Related Experiment Video
Updated: Jan 22, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist
1Ivy Brain Tumor Center, Barrow Neurological Institute, Phoenix, Arizona.
Abstract:
In an era of escalating drug discovery costs, shifting priorities within the pharmaceutical industry, and longstanding challenges in central nervous system drug delivery, surgical trials offer an avenue to identify promising agents with demonstrable tumor penetration and molecular effects. The rise of pharmacodynamic- and pharmacokinetic-driven clinical trials, including phase 0 study designs, creates an opportunity for the neurosurgical oncologist to engage drug development for brain tumor patients directly. Here, we review the phase 0 clinical trial mechanism as well as its current and future applications within neurosurgical oncology.
Insights
Phase 0 clinical trials offer a novel approach for neurosurgical oncologists to directly engage in brain tumor drug development. These trials assess drug penetration and effects, addressing challenges in central nervous system delivery and high discovery costs.
Area of Science:
- Neurosurgical Oncology
- Clinical Pharmacology
- Drug Discovery
Background:
- Rising drug discovery costs and challenges in central nervous system (CNS) drug delivery necessitate innovative approaches.
- Shifting pharmaceutical industry priorities impact the development of treatments for complex diseases like brain tumors.
Purpose of the Study:
- To review the mechanism of phase 0 clinical trials.
- To explore the current and future applications of phase 0 trials in neurosurgical oncology.
- To highlight the role of neurosurgical oncologists in advancing brain tumor drug development.
Main Methods:
- Review of phase 0 clinical trial designs and their relevance to neuro-oncology.
- Analysis of pharmacodynamic and pharmacokinetic data in early-phase trials.
- Discussion of surgical trial integration in drug development.
Main Results:
- Phase 0 trials enable direct assessment of drug tumor penetration and molecular effects.
- These trials provide a platform for neurosurgical oncologists to actively participate in drug development.
- Pharmacodynamic- and pharmacokinetic-driven designs optimize early-stage drug evaluation.
Conclusions:
- Phase 0 clinical trials represent a valuable strategy for evaluating novel agents in brain tumor patients.
- Neurosurgical oncology can leverage these trials to overcome CNS drug delivery hurdles.
- This approach facilitates the identification of promising drugs with proven efficacy in the brain tumor microenvironment.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Phase Diagrams
Phase Transitions

